Inflamalps is a biopharmaceutical company established in Valais, Switzerland.
Inflamalps’ mission is to discover anti-inflammatory and anti-microbial new molecules.
Inflamalps is developing INF101 for the treatment of dry eye in ophthalmology.
Since 2020, Inflamalps is leading a drug discovery effort to discover novel anti-microbial molecules
in partnership with the University of Turin in Italy, the University of Canterbury in New-Zealand, the Haute Ecole d’ingénierie et d'architecture de Fribourg in Switzerland and the microbiology specialized CRO IHMA in Switzerland.